Medical AI Alliance
← Company Index
Healthcare InfrastructureKOSPI 1618904 approvals9 trials

KOLMAR KOREA CO.,LTD

Official website

Founded and listed on KOSPI in 2012 upon spin-off from the former Kolmar Korea, KOLMAR KOREA runs cosmetics ODM, prescription drugs, and packaging.

As of 2026-10-10, KOLMAR KOREA CO.,LTD has 4 Korean MFDS device approvals, 55 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded and listed on KOSPI in 2012 via spin-off from Kolmar Korea, it runs cosmetics ODM, prescription drugs, and packaging. Over 95% of cosmetics revenue is ODM; HK inno.N makes drugs for circulatory, diabetes, cancer, and kidney conditions, while Yonwoo supplies cosmetics containers split about 50/50 domestic/export. HK inno.N develops IN-114199, IN-115314, and GLP-1 drug IN-B00009.

Products & technology

  • Cosmetics ODM (basic, functional, color)Cosmetics ODM manufacturing
  • Prescription drugs (circulatory, diabetes, cancer, kidney) and APIsPrescription drugs and active pharmaceutical ingredients
  • Pump and tube cosmetics containers (Yonwoo)Cosmetics packaging
  • Condition, Heotgaesu, HongsamjinH&B health functional food

Regulatory approvals

data.go.kr

4 Korean MFDS device approvals · 2008–2024

  • MFDSDressing, fluid-impermeable film2024-12-24
    Product approval · Class 2제인 24-1175 호
  • MFDSGel for medical use, non-sterilized2024-10-25
    Product approval · Class 1제신 24-1308 호
  • MFDSDressing, fluid-impermeable film2022-05-27
    Product approval · Class 2제인 22-4417 호
  • MFDSIrrigation unit, vaginalRevoked2008-11-25
    Product approval · Class 2수허 08-1159 호

Clinical trials

data.go.kr

9 MFDS clinical trial authorisations · 2012–2019 (Phase 1 7 · Phase 2 2)

  • Phase 1KKM-1842019-12-30

    1 trial site

  • Phase 1KKM-1542019-06-20

    1 trial site

  • Phase 1KKM-1742019-01-23

    1 trial site

  • Phase 1KKM-1542018-08-31

    1 trial site

  • Phase 1KKM-1712018-05-04

    1 trial site

  • Phase 1KKM-1712017-09-08

    1 trial site

  • Phase 1KKM-1642017-08-03

    1 trial site

  • Phase 2KKMDM-012013-02-25

    1 trial site

  • Phase 2NDM101072012-09-20

    1 trial site

R&D and key agreements

Source: DART corporate disclosure

IN-114199 · 만성변비치료제 · 국내 임상1상 · Developed by HK inno.N

IN-115314 · 자가면역질환 · 인체용 국내 임상2상, 동물용 국내 임상3상 · Developed by HK inno.N

IN-B00009 · 비만치료제(GLP-1) · 국내 임상3상 · Developed by HK inno.N

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 45 more publications

Patents

KIPRIS · applicant-matched
Show 990 more patents

AI reads

MAA server logs · IP-verified
86
Times AI engines pulled KOLMAR KOREA CO.,LTD's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

85
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

17
live 0
Last 7 days
73
live 1
Last 30 days
86
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot67
  • GoogleGoogleOther7
  • MicrosoftBingbot6
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KOLMAR KOREA CO.,LTD and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsHealthcare Infrastructure

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Dong-A Socio Holdings Co.,Ltd2 shared

Founded 1949, KOSPI-listed 1970, Dong-A Socio Holdings makes Bacchus and pharma/non-pharma goods, allied with Meiji Seika on biosimilars.

DONGWHA PHARM.CO.,LTD1 shared

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

BIO-FD&C CO.,LTD.1 shared

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

Tego Science, Inc.1 shared

Tego Science makes cell therapies Holoderm and Rosmir, and sells the 3D skin model Neoderm for CDMO and animal-alternative testing.

DaehanPharmaceutical1 shared

Daehan Pharmaceutical, founded in 1963 and KOSDAQ-listed in 1994, manufactures intravenous fluid pharmaceuticals.

WON TECH CO.,Ltd.1 shared

Founded in 2019 and KOSDAQ-listed the same year, WON TECH makes aesthetic laser, RF, and HIFU devices including Oligio and Picocare.

PharmaResearch Co., Ltd.1 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

Humedix Co., Ltd.1 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

Wonbiogen Co.,Ltd.1 shared

Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.

BIO PROTECH INC.1 shared

Manufactures biosensors for electronic medical device consumables, including ECG measurement electrodes.

DongKookPharmaceuticalCo.,Ltd.1 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

GFC Life Science Co., Ltd.1 shared

Founded in 2002 and listed on KOSDAQ in 2025, GFC Life Science develops skin microbiome and exosome-based cosmetic materials and provides clinical testing services.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition